 |
Vol.63 No.6 contents | Japanese/English |
 | Full Text of PDF (1217K) Article in Japanese |
- Case Report -
Small Cell Lung Cancer Treated by Atezolizumab Without the Exacerbation of Lambert-Eaton Myasthenic Syndrome: a Case Report
Hanae Higa1, Takeaki Miyata1, Takashi Yoshimatsu21Department of General Thoracic Surgery, Shin-Kuki General Hospital, Japan, 2Department of General Thoracic Surgery, Fukuoka Wajiro Hospital, Japan
Background. In the treatment of lung cancer, cancer immunotherapy with immune checkpoint inhibitors (ICIs) may cause or exacerbate immune-related adverse events (irAEs) in patients with pre-existing autoimmune diseases. Case. A 72-year-old man was referred to our hospital with complaints of fever and back pain. After a thorough medical examination, he was diagnosed with extensive stage small cell lung cancer (SCLC) complicated by Lambert-Eaton myasthenic syndrome (LEMS) and obstructive pneumonia. After receiving carboplatin/etoposide plus atezolizumab therapy, he is currently on maintenance therapy with atezolizumab. Conclusion. Although there are several reports of LEMS as an irAE caused by ICI therapy, we report a case of SCLC complicated by LEMS, in which the patient was treated with atezolizumab, and in which both LEMS and SCLC had an uneventful course.
key words: Small cell lung cancer (SCLC), Lambert-Eaton myasthenic syndrome (LEMS), Immune checkpoint inhibitor (ICI), Atezolizumab
Received: April 21, 2023
Accepted: June 15, 2023
JJLC 63 (6): 882-886, 2023
